The Metabolic Hypothesis of Alzheimer’s Disease: Exploring New Frontiers

Alzheimer's disease has long been associated with amyloid plaques and tau tangles. However, recent metabolic research has shifted some focus toward insulin signaling dysfunction in the brain. This emerging perspective is crucial for understanding the complexities of Alzheimer’s.

The concept of “type 3 diabetes” gained traction following the seminal 2008 paper by de la Monte & Wands. They described impaired insulin and IGF signaling in Alzheimer’s brains. Their findings proposed that insulin resistance may contribute to several factors, including:

• Amyloid-β accumulation

• Tau hyperphosphorylation

• Oxidative stress

• Synaptic dysfunction

• Neuronal loss

  
  

While “type 3 diabetes” is not a formal diagnostic category, the biological overlap between metabolic dysfunction and neurodegeneration is now well documented.

GLP-1 and Alzheimer’s Disease: What Does the Evidence Show?

Alzheimer’s disease is often characterized by:

• Brain insulin resistance

• Reduced cerebral glucose uptake (visible on FDG-PET imaging)

• Neuroinflammation and microglial activation

• Increased oxidative stress

• Mitochondrial dysfunction

  
  

This metabolic framing naturally raises a therapeutic question.

Why GLP-1 Receptor Agonists Entered the Conversation

In my previous article, The Future of GLP-1 Receptor Drugs: What to Expect by 2028, I explored how these agents are evolving beyond glycemic control into systemic metabolic regulators. Here, we examine their potential relevance to Alzheimer’s disease.

Systemic Effects Relevant to Neurodegeneration

GLP-1 receptor agonists have several systemic effects that may be relevant to neurodegeneration:

• Improved insulin sensitivity

• Anti-inflammatory actions

• Reduction in oxidative stress

• Potential mitochondrial support

• Effects on appetite regulation and metabolic flexibility

  
  

Importantly, GLP-1 receptors are expressed in the central nervous system, including the brain and spinal cord, where they suppress food-seeking behavior. Preclinical work, extensively discussed by Hölscher C. (2024), suggests that GLP-1 receptor activation may:

• Reduce neuroinflammation

• Improve synaptic plasticity

• Support neuronal survival through mitochondrial function

  
  

This created genuine enthusiasm.

Observational Studies: Promising Signals

Two large real-world analyses led by Liqiang Wang (2024, Alzheimer’s & Dementia) reported:

• Reduced incidence of Alzheimer’s-related dementia among semaglutide users

• Lower risk of first Alzheimer’s diagnosis compared to other antidiabetic agents

  
  

These studies employed target-trial emulation methods, which are sophisticated but still observational. This is the crucial distinction: Association ≠ causation.

Residual confounding, selection bias, and healthier-user effects remain possible explanations. They generate hypotheses. They do not establish disease modification.

Wang L et al. "Association of semaglutide with risk of Alzheimer’s disease–related dementia in patients with type 2 diabetes: a target trial emulation study" Alzheimers Dement
. 2024,

[Wang L et al. "Semaglutide and risk of first diagnosis of Alzheimer’s disease: a nationwide real-world study" ](https://pubmed.ncbi.nlm.nih.gov/39445596/Alzheimers Dement
. 2024.

Preclinical Evidence

In APP/PS1 mouse models, which express Amyloid Precursor Protein (APP), semaglutide has been shown to:

• Reduce microglial activation

• Improve memory task performance

• Decrease neuroinflammatory markers

  
  

However, not all models show consistent benefits. Rodent models do not fully replicate human Alzheimer’s, and translation failure in neurodegeneration is common.

You know this well: the history of Alzheimer’s therapeutics is full of elegant mechanisms that failed in humans. Animal models have demonstrated the potential neuroprotective effects of GLP-1 receptor agonists. However, preclinical findings are not entirely consistent across all Alzheimer’s models, and translation from animal models to human disease remains challenging.

Li Y et al. Semaglutide improves cognitive impairment and reduces neuroinflammation in APP/PS1 mice. Brain Behav Immun
. 2024.

The Critical Test: Randomised Clinical Trials

The Phase III EVOKE and EVOKE+ trials are the first large-scale studies investigating the disease-modifying potential of semaglutide in participants with early-stage symptomatic Alzheimer’s disease. These trials include exploration of effects on Alzheimer’s biomarkers and neuroinflammation.

Results reported include:

• AD biomarkers and neuroinflammation were reduced

• Primary cognitive endpoints were not met

• No significant slowing of cognitive decline versus placebo

  
  

The trials will provide data on the potential disease-modifying effects of semaglutide. They will be important in evaluating its utility in treating early-stage symptomatic Alzheimer’s. The completion of the trials' main phase was in September 2025, and the 52-week extension will continue to October 2026.

Mechanistic plausibility and observational data did not translate into demonstrated cognitive benefit in symptomatic disease. That doesn’t invalidate the metabolic hypothesis, but it limits current clinical claims.

Hope on the Horizon: Exploring Next-Generation GLP-1 Incretin Drugs

Julio P. Frias and colleagues (2024, J Clin Invest) discuss emerging multi-agonist therapies, including:

• GLP-1/GIP dual agonists

• GLP-1/GIP/glucagon triple agonists

  
  

The hypothesis is that broader metabolic and anti-inflammatory signaling may exert stronger systemic and possibly central effects. However, robust randomized data in Alzheimer’s populations remain limited.

Dual and triple incretin agonists (GLP-1/GIP and GLP-1/GIP/glucagon combinations) may exert broader metabolic, anti-inflammatory effects and possibly central nervous system effects.

Frias JP et al., "Emerging multi-agonist incretin therapies and their potential in metabolic and neurodegenerative disease". J Clin Invest
. 2024.

Where We Actually Stand

• The metabolic hypothesis is biologically plausible.

• Brain insulin resistance is well-documented.

• Observational signals are intriguing.

• Phase III semaglutide trials in symptomatic Alzheimer’s were negative.

• Next-generation incretins remain investigational.

  
  

Final Perspective

The exploration of GLP-1–based therapies in Alzheimer's disease reflects a broader shift:

• Neurodegeneration is no longer viewed as an isolated brain pathology.

• It is increasingly understood as a systemic, metabolic–inflammatory disorder with central manifestations.

• At present, GLP-1 receptor agonists are not established treatments for Alzheimer’s disease. But the metabolic lens is not going away.

• The next decade will likely focus less on amyloid alone and more on systemic resilience, metabolic integrity, and early intervention.

  
  

In conclusion, the ongoing research into the metabolic aspects of Alzheimer’s disease presents a promising avenue for future therapies. Understanding the interplay between metabolism and neurodegeneration will be essential in developing effective interventions.